Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xiaoyan Li, Ying Yin, Wenfeng Li, Shanshan Li, Dandan Zhang & Zehong Liu. (2022) Omarigliptin alleviates cognitive dysfunction in Streptozotocin-induced diabetic mouse. Bioengineered 13:4, pages 9387-9396.
Read now
Read now
Richard A. Chudleigh & Steve C Bain. (2020) Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. Current Medical Research and Opinion 36:2, pages 209-211.
Read now
Read now
Dimitrios Stoimenis, Thomas Karagiannis, Anastasia Katsoula, Eleni Athanasiadou, Kyriakos Kazakos, Eleni Bekiari, David R. Matthews & Apostolos Tsapas. (2017) Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy 18:9, pages 843-851.
Read now
Read now
Articles from other publishers (14)
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Crossref
Yang Liu, Shuai Yan, Jie Liu, Hongzhong Liu, Ling Song, Xueting Yao, Ji Jiang, Fangqiong Li, Ke Du, Dongyang Liu & Pei Hu. (2023) Development and validation of an HPLC coupled with tandem mass spectrometry method for the determination of HSK7653, a novel super long‐acting dipeptidyl peptidase‐4 inhibitor, in human plasma and urine and its application to a pharmacokinetic study. Biomedical Chromatography 37:5.
Crossref
Crossref
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Yu. V. Gorbunova, E. V. Volotova, I. E. Makarenko, V. B. Saparova, R. V. Drai & V. I. Petrov. (2023) Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use. Pharmacy & Pharmacology 11:1, pages 19-47.
Crossref
Crossref
Noha A. Gouda & Jungsook Cho. (2022) Omarigliptin Mitigates 6-Hydroxydopamine- or Rotenone-Induced Oxidative Toxicity in PC12 Cells by Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Actions. Antioxidants 11:10, pages 1940.
Crossref
Crossref
Haidy E. Michel, Mariam M. Tadros, Moataz S. Hendy, Shereen Mowaka & Bassam M. Ayoub. (2022) Omarigliptin attenuates rotenone-induced Parkinson's disease in rats: Possible role of oxidative stress, endoplasmic reticulum stress and immune modulation. Food and Chemical Toxicology 164, pages 113015.
Crossref
Crossref
Amit Gupta, Tapan Behl, Aayush Sehgal, Shaveta Bhardwaj, Sukhbir Singh, Neelam Sharma & Abdul Hafeez. (2021) Exploring the recent molecular targets for diabetes and associated complications. Molecular Biology Reports 48:3, pages 2863-2879.
Crossref
Crossref
Bassam M. Ayoub, Haidy E. Michel, Shereen Mowaka, Moataz S. Hendy & Mariam M. Tadros. (2021) Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS. Molecules 26:4, pages 889.
Crossref
Crossref
Cristhian Reynaldo Gomez Bautista, Ingrid Valadares dos Santos, Renata Mendonça Moraes, Fernando Yamamoto Chiba, Doris Hissako Sumida, Michele Bianchi de Moraes, Luana Marotta Reis de Vasconcellos & Ana Lia Anbinder. (2019) Sitagliptin’s effects on bone tissue and osseointegration in diabetic rats. Archives of Oral Biology 102, pages 238-243.
Crossref
Crossref
Bassam M. Ayoub, Shereen Mowaka, Marwa M. Safar, Nermeen Ashoush, Mona G. Arafa, Haidy E. Michel, Mariam M. Tadros, Mohamed M. Elmazar & Shaker A. Mousa. (2018) Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent. Scientific Reports 8:1.
Crossref
Crossref
Hitoshi Ishii, Hiroki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri & Yasuhiro Akai. (2018) Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). Diabetes Therapy 9:3, pages 1001-1019.
Crossref
Crossref
Bassam M. Ayoub, Shereen Mowaka & Mona G. Arafa. (2018)
Factorial design optimization of micelle enhanced synchronous spectrofluorimetric assay of Omarigliptin: Applied to content uniformity testing and
in vitro
drug release
. Luminescence 33:4, pages 797-805.
Crossref
Crossref
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye & Jianming Wu. (2018) Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 9.
Crossref
Crossref
Gaurav Chikara, Pramod Kumar Sharma, Pradeep Dwivedi, Jaykaran Charan, Sneha Ambwani & Surjit Singh. (2017) A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?. Indian Journal of Clinical Biochemistry 33:2, pages 121-131.
Crossref
Crossref
Jun Yang, Chao Huang, Shanshan Wu, Yang Xu, Ting Cai, Sanbao Chai, Zhirong Yang, Feng Sun & Siyan Zhan. (2017) The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. PLOS ONE 12:12, pages e0187537.
Crossref
Crossref